These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 22257913)
1. [Biotechnological innovation to the benefit of the rheumatic patient]. Minisola G Reumatismo; 2011 Nov; 63(3):125-8. PubMed ID: 22257913 [No Abstract] [Full Text] [Related]
2. Costs of pain in rheumatology. Marsico A; Atzeni F; Piroddi A; Cazzola M; Stisi S; Sarzi-Puttini P Reumatismo; 2014 Jun; 66(1):103-7. PubMed ID: 24938203 [TBL] [Abstract][Full Text] [Related]
3. The Corrona US registry of rheumatic and autoimmune diseases. Kremer JM Clin Exp Rheumatol; 2016; 34(5 Suppl 101):S96-S99. PubMed ID: 27762197 [TBL] [Abstract][Full Text] [Related]
4. [Can we treat with modern antirheumatics? Costs of NSAID treatment]. Bolten WW Pharm Unserer Zeit; 2002; 31(2):206-15. PubMed ID: 11977457 [No Abstract] [Full Text] [Related]
5. Do rheumatology cost-effectiveness analyses make sense? Wolfe F; Michaud K; Pincus T Rheumatology (Oxford); 2004 Jan; 43(1):4-6. PubMed ID: 14523227 [No Abstract] [Full Text] [Related]
6. Rheumatologic rehabilitation: the great expectation for rheumatic patients. Maddali Bongi S; Matucci Cerinic M Reumatismo; 2012 Mar; 64(1):1-6. PubMed ID: 22472777 [No Abstract] [Full Text] [Related]
7. Recent advances in Pediatric Rheumatology: July 2015-June 2016. Sharma A; Vignesh P; Jindal AK; Gupta A Int J Rheum Dis; 2017 Apr; 20(4):504-509. PubMed ID: 28205425 [No Abstract] [Full Text] [Related]
8. [Solutions for off-label therapy]. Schmidt WA Z Rheumatol; 2003; 62(Suppl 2):II54-6. PubMed ID: 14648094 [TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomics of Biosimilars: What Is There to Gain from Them? Araújo FC; Gonçalves J; Fonseca JE Curr Rheumatol Rep; 2016 Aug; 18(8):50. PubMed ID: 27402107 [TBL] [Abstract][Full Text] [Related]
11. Pharmacoepidemiology and rheumatic disorders. Chan KA; Hernandez-Diaz S Rheum Dis Clin North Am; 2004 Nov; 30(4):835-50, vii. PubMed ID: 15488696 [TBL] [Abstract][Full Text] [Related]
12. Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data. Silman A; Shipley M Br J Rheumatol; 1997 May; 36(5):599-601. PubMed ID: 9189064 [No Abstract] [Full Text] [Related]
13. [National registry for a new and costly treatment]. Uhlig T; Nordvåg BY Tidsskr Nor Laegeforen; 2008 Aug; 128(15):1654. PubMed ID: 18704130 [No Abstract] [Full Text] [Related]
14. Give observational studies a chance: better observational studies make better economic evaluations. Maetzel A; Bombardier C J Rheumatol; 1999 Nov; 26(11):2298-9. PubMed ID: 10555880 [No Abstract] [Full Text] [Related]
15. The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. Wolfe F; Michaud K Rheumatology (Oxford); 2011 Jan; 50(1):16-24. PubMed ID: 20566735 [TBL] [Abstract][Full Text] [Related]
16. [Medical and economic aspects of rheumatoid arthritis]. Fautrel B; Gaujoux-Viala C Bull Acad Natl Med; 2012 Oct; 196(7):1295-305; discussion 1305-6. PubMed ID: 23815015 [TBL] [Abstract][Full Text] [Related]
17. Economic issues with new rheumatologic therapeutics. Kavanaugh A Curr Opin Rheumatol; 2007 May; 19(3):272-6. PubMed ID: 17414954 [TBL] [Abstract][Full Text] [Related]
18. Musculoskeletal disorders--disease burden and challenges in the developing world. Gcelu A; Kalla AA S Afr Med J; 2015 Dec; 105(12):1070-1. PubMed ID: 26933718 [No Abstract] [Full Text] [Related]